Comparison

C1 Esterase Inhibitor (C1IN, C1 Inh, C1Inh, C1-INH, C1NH, C1-inhibiting Factor, HAE1, HAE2, Plasma Protease C1 Inhibitor, Serpin G1, SERPING1)

Item no. USB-C0003-01E
Manufacturer United States Biological
Amount 1 mg
Category
Type Antibody Polyclonal
Format Liquid
Applications WB, FC, IF, IHC, ELISA, IC
Specific against Human (Homo sapiens)
Host Sheep
Isotype IgG
Purity Purified by immunoaffinity chromatography. ≥95% on SDS-PAGE.
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping Condition Cool pack
Available
Manufacturer - Type
Pab
Manufacturer - Category
Antibodies / Antibodies-Protease Inhibitors
Shipping Temperature
Blue Ice
Storage Conditions
-20°C
Grade
Affinity Purified
Form
Supplied as a liquid in 10mM sodium phosphate, 0.15M sodium chloride, pH 7.2, 0.05% sodium azide.
EU Commodity Code
30021010
Immunogen
Purified Human C1 Inhibitor
Specificity
Recognizes human C1 Inhibitor.
Description
C1-INH is a member of the serpin family of proteases, as are alpha-antitrypsin, antithrombin III, and angiotensinogen. These proteins stoichiometrically inactivate their target proteases by forming stable, one-to-one complexes with the protein to be inhibited. Although synthesized primarily by hepatocytes, C1-INH is also synthesized by monocytes. The regulation of the protein production is not completely understood, but, since patients respond clinically to androgen therapy serum levels of C1-INH increase, it is believed that androgens may stimulate C1-INH synthesis. All C1-INH deficient patients are heterozygous; half the normal level of C1-INH is not believed sufficient to prevent attacks. Although named for its action on the first component of complement (C1 esterase), C1-INH also inhibits components of the fibrinolytic, clotting, and kinin pathways. Specifically, C1-INH inactivates plasmin-activated Hageman factor (factor XII), activated factor XI, PTA, and kallikrein. Within the complement system, C1-INH blocks the activation of C1 and the rest of the classic complement pathway by binding to C1r and C1s. Without C1-INH, unchecked activation of C1, C2, and C4 occur before other inhibitors (C4-binding protein and factor I) can halt the cascade. The actual factor or factors responsible for the edema formation remain somewhat controversial. Researchers have demonstrated activation of the kinin system and increased bradykinin concentration associated with clinical flares.

Applications:
Suitable for use in ELISA, Western Blot, Immunocytochemistry, Immunohistochemistry, Immunofluorescence and FACS. Other applications not tested.

Recommended Dilutions:
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close